VANDA Pharmaceuticals - Investor Relations - IR Home

Investor Relations

Press Releases

Print Page Print Page
<< Back
Tradipitant in the Treatment of Gastroparesis: Vanda Presents Clinical Trial Results at DDW 2019

WASHINGTON, May 22, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced the results of the Phase II study of tradipitant in gastroparesis were presented at Digestive Disease Week® (DDW) 2019 in San Diego, CA. 

For more information on DDW 2019, please refer to

About Vanda

Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients.  For more on Vanda Pharmaceuticals Inc., please visit

Investor Contact:
Jim Kelly
Executive Vice President & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428

Media Contacts:
AJ Jones II
Burson Cohn & Wolfe (BCW)
1110 Vermont Avenue, NW, Suite 1200
Washington, D.C. 20005

Elizabeth Van Every
Burson Cohn & Wolfe (BCW)
230 Park Avenue South
New York, NY 10003

Cision View original content:

SOURCE Vanda Pharmaceuticals Inc.

Copyright © 2005-2021 Vanda Pharmaceuticals Inc. |